Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To investigate the expression of
MT1F
gene in hepatocellular carcinoma tissue and the growth suppression effect of exogenous introduction of
MT1F
gene on liver cell line HepG2 and to explore the potential application of
MT1F
gene in gene therapy of tumor. Eukaryotic expression vector of pCMV-
MT1F
plasmid was introduced into HepG2 line which expressed no
MT1F
protein originally with lipofectamine transfection method. The cell growth curve, soft agar colony formation rate and tumorigenicity in SCID mice were examined to demonstrate the growth suppression effect of exogenous
MT1F
gene on HepG2 cell line. The
MT1F
mRNA and
MT1F
protein were also detected in 60 pairs of surgical specimens of hepatocellular carcinoma by in situ hybridization and immunohistochemistry. The transfected HepG2 cell line grew more slowly than control HepG2 as shown by cell growth curves, the soft agar colony formation rate (3.8 percent vs. 7.4 percent, p <.01) and the average growth rate of tumor in SCID mice (30.9 +/- 6.9 vs. 70.3 +/- 5.6, p <.01). The expression level of
MT1F
mRNA and protein significantly increased in paracancerous tissue, normal tissue than in cancer tissues (75 percent, 70 percent vs. 16.7 percent by ISH and 66.7 percent, 60 percent vs. 10 percent by IHC, p <.01). Exogenous
MT1F
gene shows the strong effect of growth inhibition on HepG2 cell line. In the
liver cancer
tissue,
MT1F
shows down-regulated expression that supports the inhibited function of
MT1F
in cancer growth and suggests
MT1F
may have an important role in gene therapy of hepatocellular carcinoma.
...
PMID:The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma. 1536 32